_________________
______________
_____________
____________________ ___________________
_______________ _______________
_______________
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use
KRAZATI safely and effectively. See full prescribing information for
KRAZATI.
KRAZATI
™
(adagrasib) tablets, for oral use
Initial U.S. Approval: 2022
__________________
INDICATIONS AND USAGE
KRAZATI is an inhibitor of the RAS GTPase family indicated for the
treatment of adult patients with KRAS G12C-mutated locally advanced or
metastatic non-small cell lung cancer (NSCLC), as determined by an FDA
approved test, who have received at least one prior systemic therapy. (1)
This indication is approved under accelerated approval based on objective
response rate (ORR) and duration of response (DOR). Continued approval for
this indication may be contingent upon verification and description of a
clinical benefit in a confirmatory trial(s). (1)
_______________
DOSAGE AND ADMINISTRATION
• Recommended dosage: 600 mg orally twice daily. (2.2)
• Swallow tablets whole with or without food. (2.2)
______________
DOSAGE FORMS AND STRENGTHS
Tablets: 200 mg. (3)
CONTRAINDICATIONS
None. (4)
WARNINGS AND PRECAUTIONS
• Gastrointestinal Adverse Reactions: Monitor patients for diarrhea, nausea
and vomiting and provide supportive care as needed. Withhold, reduce the
dose or permanently discontinue based on severity. (2.3, 5.1)
• QTc Interval Prolongation: Avoid concomitant use of KRAZATI with
other products with a known potential to prolong the QTc interval.
Monitor ECG and electrolytes in patients at risk, and in patients taking
medications known to prolong the QT interval. Withhold, reduce the dose,
or permanently discontinue based on severity. (
2.3, 5.2)
• Hepatotoxicity: Monitor liver laboratory tests prior to the start of
KRAZATI and monthly for 3 months after and as clinically indicated.
Reduce the dose, withhold, or permanently discontinue based on severity.
(2.3, 5.3)
• Interstitial Lung Disease / Pneumonitis: Monitor for new or worsening
respiratory symptoms. Withhold KRAZATI for suspected
ILD/pneumonitis and permanently discontinue if no other potential causes
of ILD/pneumonitis are identified. (
2.3, 5.4)
____________________
ADVERSE REACTIONS
____________________
• The most common (≥ 25%) adverse reactions were nausea, diarrhea,
vomiting, fatigue, musculoskeletal pain, hepatotoxicity, renal impairment,
edema, dyspnea, and decreased appetite. (6.1)
• The most common Grade 3 or 4 (≥ 2%) laboratory abnormalities were
decreased lymphocytes, decreased hemoglobin, increased alanine
aminotransferase, increased aspartate aminotransferase, hypokalemia,
hyponatremia, increased lipase, decreased leukocytes, decreased
neutrophils and increased alkaline phosphatase. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Mirati
Therapeutics, Inc. at 1-844-MIRATI-1 (1-844-647-2841) or FDA at
1-800-FDA-1088 or www.fda.gov/medwatch.
____________________
DRUG INTERACTIONS
____________________
See full prescribing information for clinically significant drug interactions
with KRAZATI. (7)
• Strong CYP3A4 Inducers: Avoid concomitant use. (7.1
)
• Strong CYP3A4 Inhibitors: Avoid concomitant use until adagrasib
concentrations have reached steady state. (7.1)
• Sensitive CYP3A4 Substrates: Avoid concomitant use with sensitive
CYP3A4 substrates. (7.2)
• Sensitive CYP2C9 or CYP2D6 Substrates or P-gp Substrates: Avoid
concomitant use with sensitive CYP2C9 or CYP2D6 substrates or P-gp
substrates where minimal concentration changes may lead to serious
adverse reactions. (7.2)
• Drugs That Prolong QT Interval: Avoid concomitant use with KRAZATI.
(7.3)
USE IN SPECIFIC POPULATIONS
_______________
Lactation: Advise not to breastfeed. (8.2)
See 17 for PATIENT COUNSELING INFORMATION and FDA-
approved patient labeling.
Revised: 12/2022
FULL PRESCRIBING INFORMATION: CONTENTS*
1
INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
2.1 Patient Selection
2.2 Recommended Dosage
2.3 Dosage Modifications for Adverse Reactions
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Gastrointestinal Adverse Reactions
5.2 QTc Interval Prolongation
5.3 Hepatotoxicity
5.4 Interstitial Lung Disease /Pneumonitis
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
7 DRUG INTERACTIONS
7.1 Effects of Other Drugs on KRAZATI
7.2 Effects of KRAZATI on Other Drugs
7.3 Drugs That Prolong QTc Interval
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Lactation
8.3 Females and Males of Reproductive Potential
8.4 Pediatric Use
8.5 Geriatric Use
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
13.2 Animal Toxicology and/or Pharmacology
14 CLINICAL STUDIES
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION
*Sections or subsections omitted from the full prescribing information are not
listed.
Reference ID: 5095255